Alliancebernstein L.P. Ngm Biopharmaceuticals Inc Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $2,580 - $5,633	-4,300 Reduced 6.27%	64,310 $55,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $4,914 - $15,771	-4,680 Reduced 6.39%	68,610 $73,000
Q2 2023 Aug 15, 2023	BUY	$2.44 - $4.53 $25,595 - $47,519	10,490 Added 16.7%	73,290 $189,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $12,276 - $17,820	3,300 Added 5.55%	62,800 $256,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $71,269 - $270,237	20,900 Added 54.15%	59,500 $298,000
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $115,322 - $190,750	10,900 Added 39.35%	38,600 $495,000
Q1 2022 May 13, 2022	SELL	$13.81 - $18.6 $26,239 - $35,340	-1,900 Reduced 6.42%	27,700 $422,000
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $724,505 - $924,311	-41,976 Reduced 58.65%	29,600 $524,000
Q3 2021 Nov 10, 2021	BUY	$20.15 - $26.19 $710,811 - $923,878	35,276 Added 97.18%	71,576 $1.51 Million
Q2 2021 Jul 30, 2021	BUY	$15.06 - $30.03 $174,696 - $348,348	11,600 Added 46.96%	36,300 $716,000
Q1 2021 May 06, 2021	SELL	$24.99 - $31.93 $127,448 - $162,843	-5,100 Reduced 17.11%	24,700 $718,000
Q4 2020 Feb 08, 2021	SELL	$16.21 - $31.44 $22,694 - $44,016	-1,400 Reduced 4.49%	29,800 $903,000
Q3 2020 Nov 12, 2020	SELL	$15.59 - $19.97 $20,267 - $25,961	-1,300 Reduced 4.0%	31,200 $496,000
Q2 2020 Aug 13, 2020	BUY	$11.97 - $23.47 $69,426 - $136,126	5,800 Added 21.72%	32,500 $642,000
Q1 2020 May 14, 2020	BUY	$10.0 - $19.51 $120,000 - $234,120	12,000 Added 81.63%	26,700 $329,000
Q4 2019 Feb 18, 2020	BUY	$9.97 - $20.28 $15,952 - $32,448	1,600 Added 12.21%	14,700 $272,000
Q3 2019 Nov 14, 2019	BUY	$13.09 - $18.19 $171,479 - $238,289	13,100 New	13,100 $181,000

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account